Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
BioViotica
17-AAG
30
CHF
CHF 30.00
In stock
BVT-0244-C100100 µgCHF 30.00
BVT-0244-M0011 mgCHF 50.00
BVT-0244-M0055 mgCHF 90.00
| Product Details | |
|---|---|
| Synonyms | 17-(Allylamino)-17-desmethoxygeldanamycin; Tanespimycin; NSC 330507 |
| Product Type | Chemical |
| Properties | |
| Formula |
C31H43N3O8 |
| MW | 585.7 |
| CAS | 75747-14-7 |
| Source/Host Chemicals | Semi-synthetic derivative from geldanamycin. |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | Red to dark red powder. |
| Solubility | Soluble in DMSO (10 mg/ml) or methanol (10 mg/ml). |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by BioViotica. |
| InChi Key | AYUNIORJHRXIBJ-DDSLGTNESA-N |
| Smiles | [H]/C1=C([H])/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H](O)[C@H](C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\1)C2=O)OC |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light when in solution. |
| Use/Stability |
Stable for at least 1 year after receipt when stored at -20°C. After reconstitution protect from light at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Potent, less toxic analog of geldanamycin (Prod. No. BVT-0196).
- Inhibits the essential ATPase activity of HSP90.
- Telomerase activity inhibitor.
- Apoptosis inducer.
- Antitumor compound.
Product References
- Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives: R.C. Schnur, et al.; J. Med. Chem. 38, 3806 (1995)
- The benzoquinoneansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin: T.W. Schulte & L.M. Neckers; Cancer Chemother. Pharmacol. 42, 273 (1998)
- Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone: P.A. Clarke, et al.; Oncogene 19, 4125 (2000)
- Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts: R. Nimmanapalli, et al.; Cancer Res. 61, 1799 (2001)
- A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors: A. Kamal, et al.; Nature 425, 407 (2003)
- Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction: I.A. Vasilevskaya, et al.; Cancer Res. 63, 3241 (2003)
- Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells: R. Villa, et al.; Carcinogenesis 24, 851 (2003)
- Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model: C.R. Williams, et al.; J. Urol. 178, 1528 (2007)
- Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers: R.K. Ramanathan, et al.; Clin. Cancer Res. 13, 1769 (2007)
- An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxy- geldanamycin and carboplatin in human ovarian cancer models: U. Banerji, et al.; Cancer Chemother. Pharmacol. 62, 769 (2008)
- HSP90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute pro-myelocytic leukemia cells: P.N. Meyer, et al.; Leuk. Res. 32, 143 (2008)
- Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis: J. Madrigal-Matute, et al.; Cardiovascular Res. 86, 330 (2010)
Related Products
